Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months. See why I rate ...
Zacks.com on MSN6d
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
MassDevice5d
FDA approves expanded label for Boston Scientific Ingevity+ pacing leads
Boston Scientific (NYSE: BSX) received FDA approval to expand the indication for its current-generation Ingevity+ pacing ...
healthday2d
FDA Approves First Flu Vaccine You Give Yourself at Home
The days of waiting for a flu shot at your doctor's office or local pharmacy may be over: The U.S. Food and Drug Admi ...
Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy
FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic ...
FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Insurancenewsnet.com13d
Does My Insurance Cover Off-Label Prescriptions
Off-label prescribing is when a medication is prescribed for a purpose not approved by the FDA. Insurance might cover off-label prescriptions, but it depends on the specific plan and often requires a ...
Nasdaq6d
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
The label expansion of Dupixent should increase ... Roche has already obtained FDA approval for Vabysmo prefilled syringe for people living with wet age-related macular degeneration, DME and ...
FiercePharma5d
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
Bristol-Myers Squibb’s KarXT Faces FDA Approval Hurdles: Analyst Issues Sell Rating Amid Labeling Concerns
Morgan Stanley analyst Terence Flynn has maintained their bearish stance on BMY stock, giving a Sell rating on September 3. Terence Flynn has ...
Yahoo Finance6d
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
The label expansion of Dupixent should increase its profit and ... in the first half of 2024 on strong demand in all regions. Roche has already obtained FDA approval for Vabysmo prefilled syringe for ...